06 February 2025
The brand effect: how different MRI machines trip up AI
A new study from researchers at the Champalimaud Foundation (CF) investigated whether artificial intelligence (AI) could analyse MRI scans to reliably tell which cancers are less aggressive and which pose a greater risk. While AI showed promise, its accuracy varied significantly depending on the MRI scanner’s brand.
31 January 2025
Welcome to the Champalimaud Clinical Centre
The Champalimaud Foundation has always been at the intersection of cutting-edge science, and exceptional care.
Specialising in cutting-edge cancer treatment, neuropsychiatry, and experimental clinical research, the Champalimaud Clinical Centre is committed to advancing personalised medicine through groundbreaking research, merging advanced technology with human-centred care.
Watch the video to see how the Champalimaud Foundation has been transforming healthcare and improving lives for the past 20 years—and how we’ll continue to do so in the future.
27 January 2025
Researchers uncover mechanisms of initiation and progression of the most common skin cancer in humans
An international team, co-led by Adriana Sánchez-Danés, principal investigator of the Cancer and Stem Cell Biology Lab at the Champalimaud Foundation, in Lisbon, has shown for the first time the important role of Survivin – a protein that has key roles in regulating cell division and inhibiting apoptosis (programmed cell death) – in the initiation and formation of a basal cell carcinoma, the most common human skin cancer. Their results have now been published in the print edition of January 8, 2025, of the journal Cell Discovery.
